KRSA Korsana Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1755237 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-264.6%
TTM EPS YoY169.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-42.2%
ROA-33.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets9.9%
Debt / equity0.00x
Current ratio10.42x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-11.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q2*2026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | $0 | $0 | $1.02M | $875,000 | $93,000 | $81,000 | $1.81M |
| R&D expense | $42,139 | $0 | $730,000 | $519,000 | $20,479 | $56,000 | $36,000 | $56,000 |
| SG&A expense | $6,135 | $1.77M | $2.48M | $1.34M | $1,478 | $1.71M | $1.50M | $1.25M |
| Operating income | -$48,274 | -$1.77M | -$3.21M | -$838,000 | -$21,957 | -$1.67M | -$1.46M | $502,000 |
| Income tax | $0 | — | — | $0 | $0 | — | — | — |
| Net income | -$46.42M | -$17.36M | -$13.51M | -$799,000 | -$21.72M | -$152,000 | -$73,000 | $530,000 |
| EPS (basic) | -3.19 | -0.41 | -0.76 | — | -39.49 | -0.11 | -0.56 | — |
| EPS (diluted) | -3.19 | -0.41 | -0.76 | — | -39.49 | -0.11 | -0.56 | — |
| Weighted avg. shares (diluted) | 13.53M | 4.25M | 4.21M | — | 550,061 | 3.07M | 2.56M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $456.22M | $1.39M | $2.82M | $154.13M | $163.88M | $3.01M | $3.64M | $10.11M |
| Receivables | — | $0 | $0 | $1.00M | $100,000 | $525,000 | $581,000 | $556,000 |
| Current assets | $460.65M | $1.51M | $3.09M | $154.60M | $5.07M | $4.02M | $4.50M | $4.22M |
| PP&E, net | $367,000 | $66,000 | $66,000 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $462.08M | $6.93M | $8.51M | $154.60M | $10.41M | $9.37M | $9.85M | $9.57M |
| Current liabilities | $44.20M | $1.84M | $1.71M | $12.49M | $877,000 | $800,000 | $1.07M | $725,000 |
| Total liabilities | $45.56M | $1.84M | $1.71M | $13.03M | $877,000 | $800,000 | $1.07M | $725,000 |
| Shareholders' equity | $391.56M | -$63.28M | -$47.03M | -$33.97M | -$21.84M | -$123,000 | $16,000 | $66,000 |
| Shares outstanding | 45.54M | 4.26M | 4.24M | 1.24M | 3.70M | 3.08M | 3.06M | 2.55M |
| Cash flow statement | ||||||||
| Operating cash flow | -$46.83M | -$1.43M | -$1.18M | -$1.58M | -$264,000 | -$503,000 | -$968,000 | $360,000 |
| Capital expenditure | $231,000 | $0 | $66,000 | — | $0 | $0 | $0 | — |
| Free cash flow | -$47.06M | -$1.43M | -$1.24M | — | -$264,000 | -$503,000 | -$968,000 | — |
| Investing cash flow | -$231,000 | $0 | -$66,000 | — | $0 | $0 | $0 | $0 |
| Financing cash flow | $351.10M | $0 | $825,000 | $251,000 | $1.83M | -$130,000 | $1.38M | $0 |
| Stock-based compensation | $15.23M | $51,000 | $58,000 | $95,000 | $209,000 | $114,000 | $114,000 | $122,000 |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.